CC 223

Drug Profile

CC 223

Alternative Names: ATG-008; CC 223

Latest Information Update: 25 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Developer Antengene Corporation; Celgene Corporation
  • Class Antineoplastics
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • No development reported Diffuse large B cell lymphoma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 20 Jul 2018 STA Pharmaceuticals and Antengene Corporation enter into a strategic partnership for the CMC development and manufacturing of Oncology drugs
  • 20 Jul 2018 Phase-II clinical trials in liver cancer in Taiwan, South Korea, China (PO)
  • 26 Mar 2018 TFDA approves IND application for ATG 008 in liver cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top